Ask AI
ProCE Banner Activity

COSMIC-021 Phase I Study: Cabozantinib Plus Atezolizumab in Metastatic Castration-Resistant Prostate Cancer

Slideset Download
Conference Coverage
Phase Ib results suggest cabozantinib plus atezolizumab may be active in mCRPC patients with visceral or extrapelvic lymph node metastases.

Released: September 21, 2021

Expiration: September 20, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Daiichi Sankyo, Inc.

Exelixis, Inc.

Ipsen Biopharmaceuticals Inc